UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000007180 |
|---|---|
| Receipt number | R000007139 |
| Scientific Title | A phase II neoadjuvant trial of sequential tri-weekly nanoparticle albumin-bound paclitaxel (Abraxane)/cyclophosphamide, with trastuzumab in HER2-positive patients, followed by 5-fluorouracil/epirubicine/cyclophosphamide (FEC) in operable breast cancer |
| Date of disclosure of the study information | 2012/02/01 |
| Last modified on | 2020/03/11 22:56:28 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2012/01/31 15:58:30 | ||
| 2 | Update | 2014/07/31 12:36:38 | Recruitment status |
|
| 3 | Update | 2015/08/18 08:12:26 | Recruitment status |
|
| 4 | Update | 2015/08/18 08:14:00 | Publication of results URL related to results and publications |
|
| 5 | Update | 2015/08/18 08:15:00 | Key inclusion criteria |
|
| 6 | Update | 2015/08/18 08:20:08 | Email |
|
| 7 | Update | 2019/08/03 08:58:20 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Name of primary person or sponsor Organization Organization Organization Address Address Tel |
|
| 8 | Update | 2019/08/03 09:03:56 | Number of participants that the trial has enrolled Results Results Results date posted |
|
| 9 | Update | 2019/08/03 09:07:36 | Date of IRB Last follow-up date |
|
| 10 | Update | 2019/08/03 09:07:56 | Recruitment status |
|
| 11 | Update | 2020/03/11 22:56:28 | UMIN ID1 |
